Luseogliflozin

Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM) . Luseogliflozin has the protential for researching type 2 diabetes[1][2].

Product Specifications

CAS Number

[898537-18-3]

Product Name Alternative

TS 071

UNSPSC

12352005

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Luseogliflozin.html

Purity

99.33

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

OC[C@@H](S1)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1C2=C(OC)C=C(C)C(CC3=CC=C(OCC)C=C3)=C2

Molecular Formula

C23H30O6S

Molecular Weight

434.55

References & Citations

[1]Anthony Markham, et al. Luseogliflozin: first global approval. Drugs. 2014 Jun;74 (8) :945-50.|[2]Jun Shirakawa, et al. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia. 2020 Mar;63 (3) :577-587.